Advanced search
Publication Cover
Immunotherapy Volume 1, 2009 - Issue 3
Submit an article Journal homepage
120
Views
0
CrossRef citations to date
0
Altmetric
Review

Immunosuppressive Therapy for Autoimmune Inner Ear Disease

Maria C Buniel1 Cleveland Clinic, Lerner Research Institute, Department of Immunology, NB30, 9500 Euclid Avenue, Cleveland, OH44195, USA. View further author information
,
Katie Geelan-Hansen1 Cleveland Clinic, Lerner Research Institute, Department of Immunology, NB30, 9500 Euclid Avenue, Cleveland, OH44195, USA. View further author information
,
Peter C Weber1 Cleveland Clinic, Lerner Research Institute, Department of Immunology, NB30, 9500 Euclid Avenue, Cleveland, OH44195, USA. View further author information
&
Vincent K Tuohy1 Cleveland Clinic, Lerner Research Institute, Department of Immunology, NB30, 9500 Euclid Avenue, Cleveland, OH44195, USA. Correspondence[email protected]
View further author information
Pages 425-434 | Published online: 24 Apr 2009

Bibliography

  • McCabe BF : Autoimmune sensorineural hearing loss.Ann. Otol. Rhinol. Laryngol.88(5 Pt 1) , 585–589 (1979).
  • Hughes GB , KinneySE, BarnaBP, CalabreseLH: Practical versus theoretical management of autoimmune inner ear disease.Laryngoscope.94(6) , 758–767 (1984).
  • Loveman DM , de Comarmond C, Cepero R, Baldwin DM: Autoimmune sensorineural hearing loss: clinical course and treatment outcome. Semin. Arthritis Rheum.34(2) , 538–543 (2004).
  • Hughes GB , KinneySE, BarnaBP, CalabreseLH: Autoimmunity in otology.Am. J. Otol.7(3) , 197–199 (1986).
  • Harris JP : Immunology of the inner ear: response of the inner ear to antigen challenge.Otolaryngol. Head Neck Surg.91(1) , 18–32 (1983).
  • Harris JP : Immunology of the inner ear: evidence of local antibody production.Ann. Otol. Rhinol. Laryngol.93(2 Pt 1) , 157–162 (1984).
  • Takahashi M , HarrisJP: Analysis of immunocompetent cells following inner ear immunostimulation.Laryngoscope98(10) , 1133–1138 (1988).
  • Ma C , BillingsP, HarrisJP, KeithleyEM: Characterization of an experimentally induced inner ear immune response.Laryngoscope110(3 Pt 1) , 451–456 (2000).
  • Singer GG , CarreraAC, Marshak-RothsteinA, MartínezC, AbbasAK: Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model.Curr. Opin. Immunol.6(6) , 913–920 (1994).
  • Trune DR , CravenJP, MortonJI, MitchellC: Autoimmune disease and cochlear pathology in the C3H/lpr strain mouse.Hear. Res.38(1–2) , 57–66 (1989).
  • Kusakari C , HozawaK, KoikeS, KyogokuM, TakasakaT: MRL/MP-lpr/lpr mouse as a model of immune-induced sensorineural hearing loss.Ann. Otol. Rhinol. Laryngol. Suppl.157 , 82–86 (1992).
  • Ruckenstein MJ , MilburnM, HuL: Strial dysfunction in the MRL-Fas mouse.Otolaryngol. Head Neck Surg.121(4) , 452–456 (1999).
  • Harris JP : Experimental autoimmune sensorineural hearing loss.Laryngoscope97(1) , 63–76 (1987).
  • Soliman AM : Experimental autoimmune inner ear disease.Laryngoscope99(2) , 188–193 (1989).
  • Yamanobe S , HarrisJP: Spontaneous remission in experimental autoimmune labyrinthitis.Ann. Otol. Rhinol. Laryngol.101(12) , 1007–1014 (1992).
  • Tomiyama S , JinnouchiK, IkezonoT, PawankarR, YagiT: Experimental autoimmune labyrinthitis induced by cell-mediated immune reaction.Acta Otolaryngol.119(6) , 665–670 (1999).
  • Garcia-Berrocal JR , Ramirez-CamachoR, TrinidadA, ZuritaM, de la Fuente R, Lobo D: Controversies and criticisms on designs for experimental autoimmune labyrinthitis. Ann. Otol. Rhinol. Laryngol.113(5) , 404–410 (2004).
  • Gloddek B , GloddekJ, ArnoldW: Induction of an inner-ear-specific autoreactive T-cell line for the diagnostic evaluation of an autoimmune disease of the inner ear.Ann. NY Acad. Sci.830 , 266–276 (1997).
  • Ikezono T , TomiyamaS, PawankarR, JinnouchiK, SuzukiY, YagiT: Passive transfer of experimental autoimmune labyrinthitis.Audiol. Neurootol.5(5) , 292–299 (2000).
  • Solares CA , EdlingAE, JohnsonJM et al.: Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides.J. Clin. Invest.113(8) , 1210–1217 (2004).
  • Ikezono T , OmoriA, IchinoseS, PawankarR, WatanabeA, YagiT: Identification of the protein product of the Coch gene (hereditary deafness gene) as the major component of bovine inner ear protein.Biochim. Biophys. Acta.1535(3) , 258–265 (2001).
  • Baek MJ , ParkHM, JohnsonJM et al.: Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss.J. Immunol.177(6) , 4203–4210 (2006).
  • Ruckenstein MJ , SarwarA, HuL, ShamiH, MarionTN: Effects of immunosuppression on the development of cochlear disease in the MRL-Fas(lpr) mouse.Laryngoscope109(4) , 626–630 (1999).
  • Trune DR , WobigRJ, KemptonJB, HefeneiderSH: Steroid treatment in young MRL.MpJ-Fas(lpr) autoimmune mice prevents cochlear dysfunction.Hear. Res.137(1–2) , 167–173 (1999).
  • Trune DR , WobigRJ, KemptonJB, HefeneiderSH: Steroid treatment improves cochlear function in the MRL.MpJ-Fas(lpr) autoimmune mouse.Hear. Res.137(1–2) , 160–166 (1999).
  • Rupprecht R , ReulJM, van Steensel B et al.: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur. J. Pharmacol.247(2) , 145–154 (1993).
  • Trune DR , KemptonJB, KessiM: Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice.Laryngoscope110(11) , 1902–1906 (2000).
  • Trune DR , KemptonJB, GrossND: Mineralocorticoid receptor mediates gluco-corticoid treatment effects in the autoimmune mouse ear.Hear. Res.212(1–2) , 22–32 (2006).
  • Trune DR , KemptonJB: Aldosterone and prednisolone control of cochlear function in MRL/MpJ-Fas(lpr) autoimmune mice.Hear. Res.155(1–2) , 9–20 (2001).
  • Mousa SA , GoncharukO, MillerD: Recent advances of TNF-α antagonists in rheumatoid arthritis and chronic heart failure.Expert Opin. Biol. Ther.7(5) , 617–625 (2007).
  • Satoh H , FiresteinGS, BillingsPB, HarrisJP, KeithleyEM: Tumor necrosis factor-a, an initiator, and etanercept, an inhibitor of cochlear inflammation.Laryngoscope112(9) , 1627–1634 (2002).
  • Peppel K , CrawfordD, BeutlerB: A tumor necrosis factor (TNF) receptor–IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity.J. Exp. Med.174(6) , 1483–1489 (1991).
  • Satoh H , FiresteinGS, BillingsPB, HarrisJP, KeithleyEM: Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation.J. Assoc. Res. Otolaryngol.4(2) , 139–147 (2003).
  • Wang X , TruongT, BillingsPB, HarrisJP, KeithleyEM: Blockage of immune-mediated inner ear damage by etanercept.Otol. Neurotol.24(1) , 52–57 (2003).
  • Lobo D , TrinidadA, Garcia-BerrocalJR, VerdaguerJM, Ramirez-CamachoR: TNF-α blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.Eur. Arch. Otorhinolaryngol.263(7) , 622–626 (2006).
  • McCabe BF : Autoimmune inner ear disease: therapy.Am. J. Otol.10(3) , 196–197 (1989).
  • Ruckenstein MJ .: Autoimmune inner ear disease. Curr. Opin. Otolaryngol. Head Neck Surg.12(5) , 426–430 (2004).
  • Ryan AF , HarrisJP, KeithleyEM: Immune-mediated hearing loss: basic mechanisms and options for therapy.Acta Otolaryngol.548(Suppl.) , 38–43 (2002).
  • Rahman MU , PoeDS, ChoiHK: Autoimmune vestibulo–cochlear disorders.Curr. Opin. Rheumatol.13(3) , 184–189 (2001).
  • Broughton SS , MeyerhoffWE, CohenSB: Immune-mediated inner ear disease: 10-year experience.Semin. Arthritis Rheum.34(2) , 544–548 (2004).
  • Zeitoun H , BeckmanJG, ArtsHA et al.: Corticosteroid response and supporting cell antibody in autoimmune hearing loss.Arch. Otolaryngol. Head Neck Surg.131(8) , 665–672 (2005).
  • Stone JH , FrancisHW: Immune-mediated inner ear disease.Curr. Opin. Rheumatol.12(1) , 32–40 (2000).
  • Sismanis A , WiseCM, JohnsonGD: Metho- trexate management of immune-mediated cochleovestibular disorders.Otolaryngol. Head Neck Surg.116(2) , 146–152 (1997).
  • Moscicki RA , San Martin JE, Quintero CH, Rauch SD, Nadol JB Jr, Bloch KJ: Serum antibody to inner ear proteins in patients with progressive hearing loss. Correlation with disease activity and response to corticosteroid treatment. JAMA272(8) , 611–616 (1994).
  • Matteson EL , TirzamanO, FacerGW et al.: Use of methotrexate for autoimmune hearing loss.Ann. Otol. Rhinol. Laryngol.109(8 Pt 1) , 710–714 (2000).
  • Matteson EL , FabryDA, FacerGW et al.: Open trial of methotrexate as treatment for autoimmune hearing loss.Arthritis Rheum.45(2) , 146–150 (2001).
  • Salley LH ,Jr, Grimm M, Sismanis A, Spencer RF, Wise CM: Methotrexate in the management of immune mediated cochleovesitibular disorders: clinical experience with 53 patients. J. Rheumatol.28(5) , 1037–1040 (2001).
  • Harris JP , WeismanMH, DereberyJM et al.: Treatment of corticosteroid- responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.JAMA.290(14) , 1875–1883 (2003).
  • Rahman MU , PoeDS, ChoiHK: Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.Otol. Neurotol.22(5) , 619–624 (2001).
  • Matteson EL , ChoiHK, PoeDS et al.: Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.Arthritis Rheum.53(3) , 337–342 (2005).
  • Cohen S , ShoupA, WeismanMH, HarrisJ: Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.Otol. Neurotol.26(5) , 903–907 (2005).
  • Lasak JM , SataloffRT, HawkshawM, CareyTE, LyonsKM, SpiegelJR: Autoimmune inner ear disease: steroid and cytotoxic drug therapy.Ear Nose Throat J.80(11) , 808–811, 815–6, 818 passim (2001).
  • Saracaydin A , KatirciogluS, KatirciogluS, KaratayMC: Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease.J. Int. Med. Res.21(4) , 192–196 (1993).
  • Street I , JobanputraP, ProopsDW: Etanercept, a tumour necrosis factor a receptor antagonist, and methotrexate in acute sensorineural hearing loss.J. Laryngol. Otol.120(12) , 1064–1066 (2006).
  • Luetje CM , BerlinerKI: Plasmapheresis in autoimmune inner ear disease: long-term follow-up.Am. J. Otol.18(5) , 572–576 (1997).
  • Goycoolea MV : Clinical aspects of round window membrane permeability under normal and pathological conditions.Acta Otolaryngol.121(4) , 437–447(2001).
  • Parnes LS , SunAH, FreemanDJ: Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.Laryngoscope109(7 Pt 2) , 1–17 (1999).
  • Chandrasekhar SS , RubinsteinRY, KwartlerJA et al.: Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents.Otolaryngol. Head Neck Surg.122(4) , 521–528 (2000).
  • Liu HJ , DongMM, ChiFL: Dexamethasone pharmacokinetics in guinea pig inner ear perilymph.ORL J. Otorhinolaryngol. Relat. Spec.68(2) , 93–98 (2006).
  • Yang J , WuH, ZhangP, HouDM, ChenJ, ZhangSG: The pharmacokinetic profiles of dexamethasone and methylprednisolone concentration in perilymph and plasma following systemic and local administration.Acta Otolaryngol.128(5) , 496–504 (2008).
  • Yang GS , SongHT, KeithleyEM, HarrisJP: Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss.Am. J. Otol.21(4) , 499–504 (2000).
  • Barkdull GC , HondarragueY, MeyerT, HarrisJP, KeithleyEM: AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis.Laryngoscope117(12) , 2174–2182 (2007).
  • Silverstein H , ChooD, RosenbergSI, KuhnJ, SeidmanM, SteinI: Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report).Ear Nose Throat J.75(8) , 468–471 (1996).
  • Garcia-Berrocal JR , IbanezA, RodriguezA et al.: Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: a physiopathologic approach.Eur. Arch. Otorhinolaryngol.263(11) , 977–982 (2006).
  • Van Wijk F , StaeckerH, KeithleyE, LefebvrePP: Local perfusion of the tumor necrosis factor α blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.Audiol. Neurootol.11(6) , 357–365 (2006).
  • Niparko JK , WangNY, RauchSD et al.: Serial audiometry in a clinical trial of AIED treatment.Otol. Neurotol.26(5) , 908–917 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.